3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Carcinoma, Renal Cell
2
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Hemangioblastoma
1
Glioblastoma
1
Adenoma, Islet Cell
1
Interventions
Cyclophosphamide
10
Temozolomide
8
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
Filgrastim
5
Etoposide
5
Carboplatin
5
Vincristine
4
sargramostim
3
Thiotepa
3
Melphalan
3
Carmustine
3
Automobiles
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
fludarabine
2
antineoplaston AS 2-1
2
antineoplaston A10
2
aldesleukin
2
Thalidomide
2
Paclitaxel
2
Irinotecan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Eflornithine
2
Donepezil
2
Biopsy
2
Bevacizumab
2
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
belzutifan
×
CNS
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled